MIB-1 labelling index is an independent prognostic marker in primary breast cancer.

Por Jansen, R. L., Hupperets, P. S., Arends, J. W., Joosten-Achjanie, S. R., Volovics, A., Schouten, H. C., Hillen, H. F.
Publicado em 1998

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

Por Rodenhuis, S, Bontenbal, M, Beex, LVAM, Smit, WM, Nooij, MA, Voest, EE, Wall, E van der, Hupperets, P, Tinteren, Harm van, Peterse, HL, Vijver, MJ van de, Vries, EGE de
Publicado no Breast Cancer Res (2005)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

Por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado em 2006

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

Por Lefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., Licitra, L., Lunghi, F., Stupp, R., Lacombe, D., Bogaerts, J., Horiot, J. C., Bernier, J., Vermorken, J. B.
Publicado em 2009